US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.
3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.
3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.
